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According to the World Health Organization, tuberculosis (TB) is the
leading cause of death by infectious disease in the world.
Tuberculosis is caused by the bacteria Mycobacterium tuberculosis
and occurs globally. Additionally, in 2017, TB was reported in all 50
states. Due to the scope of TB, strict observation of patients is
required to ensure adherence to the current drug regimen. However,
most reported cases are in developing countries where proper care is
difficult. With the emergence of multidrug-resistant TB exhibiting
resistance to current treatments, novel antibiotics are needed
urgently. Recently, our lab discovered a family of diphenyl ureas that
exhibit antimicrobial activity against several bacterial strains,
including Mycobacterium. Based on our lab’s previous results, we
have synthesized several diphenyl urea derivatives to examine their
structure-activity relationship. Herein, we report the synthesis of the
diphenyl ureas with varying nitro positions, chain lengths, and R-
groups.
Abstract Delamanid
• Globally, it is estimated that about 2 billion people are infected 
with tuberculosis (TB) 
• In 2017, 10 million new people became ill with TB
• 1.6 million of these people died
• Leading cause of death by infectious disease in the world
Figure 1. Global Incidence Rates of Tuberculosis
Treatment & Challenges
• Currently, the most effective TB treatment is a six-month course
of four antibiotics
• Isoniazid, rifampicin, pyrazinamide, and ethambutol
• Improper treatment can lead to MDR-TB
• Resistant to rifampin and isoniazid
• A six-month treatment course requires strict observation of
patients to ensure they adhere to the drug regimen
• Proper care is difficult in developing countries because of the
lack of medical support
• Side effects and toxicity are common
Figure 2. Delamanid
• Delamanid was recently approved to treat MDR-TB
• Similar to isoniazid, it inhibits the synthesis of mycolic acid in the
bacteria’s cell wall
• While we are unsure of the exact target of our antibiotics, the
structural similarities between our lead nitro functionalized DPU
and delamanid suggest that it may also target the bacteria’s ability
to make the cell wall
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A total of 10 novel nitro fictionalized diphenyl ureas were synthesized. 
Of these derivatives, 6 varied in chain length and 4 varied in R-groups.
Moving forward, we would like to finish the synthesis of our proposed 
nitro functionalized DPUs. Once the diphenyl ureas are successfully 
synthesized, they will be tested for their antimicrobial activity via kill 
zone assay test. 
Conclusion
Figure 10. Diphenyl Ureas Successfully Synthesized 
Each of the nitro functionalized diphenyl ureas made
Results
Figure 9. NMR Spectra of Typical Chain Length Nitro-DPU Derivative
Products verified by NMR analysis 
Spectra
Future Directions
Figure 4: Ester Derivatives
Kill zone assays results from previous work done in our lab. Tests 
conducted on E. coli, S. aureus, and Mycobacterium show the potency 
of the 5 ester derivatives. Work completed by Phil Dietz and Dr. 
Morgan.
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Background
Previous Work
• Previously discovered a family of diphenyl ureas
• Kill zone assay results shown below
• Most active compounds
Urea R
Zone (mm)
S. aureus E. coli
31 4-bu ester 11.8 9.0
29 -- 8.0 8.5
24 3-Cl 8.7 10.5
22 4-nitro 8.0 9.0
21 3-nitro 7.8 33.0
12 4-t-bu 11.3 10.0
11 4-i-pr 6.7 11.2
07 3,4-
dimethyl
10.7 9.5
Figure 3. Antimicrobial Activity of Diphenyl Ureas
Hypothesis
Using our previous results, we believe we can synthesize novel 
diphenyl urea derivatives in order to build a structure-activity 
relationship and create more potent antibiotics against Mycobacterium 
tuberculosis
Figure 5. Proposed Nitro-DPU Modifications
Figure 6. Retro Synthesis of Diphenyl Urea Compounds 
General synthetic plan for making the nitro functionalized diphenyl 
urea compounds
Synthesis of DPU Derivatives
Figure 7. Typical R-Group Nitro-DPU Synthesis
Starting with commercially available 4-nitrophenyl isocyanate and 4-
isopropylaniline, the diphenyl urea can be prepared in one step
Percent yield: 86%
Figure 8. Typical Chain Length Nitro-DPU Synthesis
Starting with commercially available 4-nitrophenyl isocyanate and 
aniline, the diphenyl urea can be prepared in one step
Percent yield: 96%
